Merida Biosciences
Merida Biosciences raises $121M Series A at $500M valuation
Quick Facts
Merida Biosciences: Series A Funding Round
Merida Biosciences has successfully raised $121M in Series A funding, reaching a valuation of $500M.
Company Overview
Developing therapeutics to eliminate pathogenic antibodies in autoimmune diseases
Funding Details
The Series A round was led by Bain Capital Life Sciences, with participation from Biotechnology Value Fund, Third Rock Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2024
- Employees: 40+
- Category: Biotech
Investment
Merida Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Bain Capital Life Sciences: Verified investor in Series A
- Biotechnology Value Fund: Verified investor in Series A
- Third Rock Ventures: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...